Advertisement

Topics

Endologix Company Profile

02:38 EST 22nd November 2017 | BioPortfolio

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a leading cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink® Delivery System an innovative, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The Company’s corporate office is located in Irvine, California.

Location

11 Studebaker
Irvine
California
92618
United States of America

Contact

Phone: 949.595.7200
Fax: 949.457.9561
Email: customerservice@endologix.com


News Articles [28 Associated News Articles listed on BioPortfolio]

Endologix's Nellix stent graft gets IDE from FDA

The FDA granted Endologix an investigational device exemption to conduct a 90-patient clinical trial of its second-generation -More- 

Endologix, Japanese distributor reach R&D, distribution deals

Endologix and Japan Lifeline signed two agreements to jointly support research, development and commercialization of novel en -More- 

Data show positive results for Endologix's endografts

Preliminary data from a 458-patient study showed Endologix's AFX and AFX2 endografts demonstrated an 84.7% rate of freedom fr -More- 

Endologix, Inc. to Present at the Piper Jaffray 29th Annual Healthcare Conference

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, will present a...

Endologix, Inc. to Present at the Stifel 2017 Healthcare Conference

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, and Vaseem Mah...

Endologix, Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, and Vaseem Mah...

EU OKs Endologix's endovascular aneurysm sealing system with refined IFU

Endologix's Nellix Endovascular Aneurysm Sealing System with the refined indications for use was granted CE mark approval by  -More- 

Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix, Inc. (Nasdaq:ELGX) (“Endologix”), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to ...

Drugs and Medications [0 Results]

None

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Retrospective Review of Billowing Phenomenon - A Mimic of Endoleak Following Placement of Endologix Covered Stent for the Treatment of Abdominal Aortic Aneurysm.

Billowing is a unique CT finding of the Endologix stent graft where a rim of contrast is observed outside the stent's endoskeleton but still contained within the graft cover. The purpose of this study...

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Safety and Effectiveness Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix® System

The objective of this study is to assess the safety and effectiveness of the Endologix Nellix® System for the endovascular repair of infrarenal abdominal aortic aneurysms (AAA).

Companies [2 Associated Companies listed on BioPortfolio]

Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the tre...

Endologix

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of...

More Information about "Endologix" on BioPortfolio

We have published hundreds of Endologix news stories on BioPortfolio along with dozens of Endologix Clinical Trials and PubMed Articles about Endologix for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Endologix Companies in our database. You can also find out about relevant Endologix Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Stent
A stent is a small mesh tube that's used to treat narrow or weak arteries. Arteries are blood vessels that carry blood away from your heart to other parts of your body.  A stent is placed in an artery as part of a procedure called angioplasty. &...


Corporate Database Quicklinks



Searches Linking to this Company Record